NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.In vitro: NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations.The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397.In vivo: The reference for NAMI-A is 35 mg/kg/day.Form:Solid.
Specifications and Purity: ≥98%
Molecular Formula: C8H15Cl4N4ORuS
Molecular Weight: 458.18
PubChem CID: 133082692
Isomeric SMILES: CS(=O)C.C1=C[NH+]=CN1.C1=CN=CN1.[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3]
- UPC:
- 85000000
- Condition:
- New
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- N646402-10mg
- CAS:
- 201653-76-1
- Product Size:
- 10mg
akash.verma@cenmed.com
(732) 447-1115





